ProfileGDS5678 / 1419401_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 72% 68% 71% 70% 70% 73% 72% 71% 69% 69% 75% 70% 70% 70% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.6223672
GSM967853U87-EV human glioblastoma xenograft - Control 24.156668
GSM967854U87-EV human glioblastoma xenograft - Control 34.5140371
GSM967855U87-EV human glioblastoma xenograft - Control 44.4344470
GSM967856U87-EV human glioblastoma xenograft - Control 54.3811270
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.6822373
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.5491972
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.4404571
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.2803169
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.2759169
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.0144175
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.3559270
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.3567770
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.3750770